Individuals or organizations who wish to have their testimony highlighted on this Interactive Public Docket should post a copy on this page
June 8-9 – Tobacco Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee
July 15-16 – Tobacco Products Scientific Advisory Committee
August 30-31 – Tobacco Products Scientific Advisory Committee
November 18-19 – Tobacco Products Scientific Advisory Committee
Please submit your comments in the “comments” section below.
House Hearing Will Draw Attention to Contraband Tobacco Issue
SPRINGFIELD, Va., May 27 /PRNewswire-USNewswire/ — The Law Enforcement Alliance of America (LEAA) today said the illegal tobacco trade is draining law enforcement resources and new policies being considered may make it worse, as the House Ways and Means Oversight Subcommittee examines the magnitude of tobacco smuggling today in the United States.
The RFI is reproduced in part below.
Please send copies of your comments to this IPD here .
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0207]
Tobacco Product Advertising and Promotion to Youth and Racial and
Ethnic Minority Populations; Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; request for data and information.
———————————————————————–
Central to the efficient operaton of TPSAC is to have its decisions based upon peer reviewed studies.
Please post studies that you believe should be subject to peer review in the “Study and Concepts Under Review” forum to the right.
In addition feel free to offer your comments on any of the studies posted on the site. You need not register or disclose your name.
To this end, please submit comments on the Hersey etal study. We would also welcome comments on our analysis of the said study.
Inside Health Policy reports:
“Long-sought draft recommendations from FDA’s Transparency Task Force on data disclosure would enable the agency to release a slew of previously veiled information to the public, sparking the ire of stakeholders, with industry saying many of the recommendations would stifle innovation and cause tension between medical product manufacturers and their investors, who proposals don’t go far enough, complaining that FDA will determine when to release data and that resource constraints will hamper the agency’s ability to redact proprietary information for public disclosure.”
In the very short period of time this Interactive Public Docket has been in operation it appears that a trend of non-transparency may be emerging within FDA’s Center for Tobacco Products.
Read herein, for example, the unwilligness of the Center to release names of an advisory committee, the sneak attack on OMB to seek the release of a gignatic paperwork submission and finally appointing members of an advisory committee who many say are biased without any public input.
A subcommittee of the FDA tobacco advisory committee is meeting on June 8 and 9.
Articles written by numerous individuals, copies of which are posted on this page , took strong exception with some of the appointments to the full committee because of alleged conflicts.
FDA should publish immediately the name of the Chair of the aforementioned subcommitee, a list of the other members of the committee and their scientific backgrounds accompanied be a web accessible list of their publications.
Upon publication of the said material, CRE will publish the information on this site for public comment.
In a surprising a move, Altria a strong proponent of the new tobacco control act , petitioned HHS to remove some panel members from the advisory committtee.
Altria states:
” .. the Appointees…have biases arising from their active and zealous participation as paid expert witnesses for plaintiffs in law suits against tobacco product maufacturers…”
HHS responds:
” A stated opinon on a scientific matter does not necessarily mean that a member would have a closed mind on a particular issue..”
Several accomplished members of the national press disagree with HHS, please see Press Comments .